^
    Back
    Association details:
    Biomarker:JAK1 S703I
    Cancer:Hepatocellular Cancer
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

    Excerpt:
    Furthermore,the sensitivity to the treatment of a JAK1/2 inhibitor, ruxolitinib, was observed in JAK1S703I mutant PDX model, but not in other non-activating mutant or wild type models.
    DOI:
    10.18632/oncotarget.6684